Ed Hurwitz, JD, MBA
Managing Director, MPM Capital

Ed Hurwitz, an accomplished biotech executive and investor, is a Managing Director at MPM Capital. He serves as Chairman of MPM portfolio companies BioIntervene and Rekindle Therapeutics, and is on the board of Dyne Therapeutics (NASDAQ: DYN) and Protego.

Prior to MPM, he was founder and Managing Director of Precision BioVentures, where he founded and seeded start-up biotechnology companies. As a Director at Alta Partners, he led 12 successful investments including Applied Genetic Technologies Corporation, Avid Radiopharmaceuticals (acquired by Lilly), Calistoga Pharmaceuticals (acquired by Gilead), Cara Therapeutics, FoldRx Pharmaceuticals (acquired by Pfizer), MacroGenics and Taligen Therapeutics (acquired by Alexion).

Over the course of his career, Mr. Hurwitz has served as Senior Vice President and CFO of Affymetrix, a microarray pioneer, and as a biotech research analyst for Robertson Stephens & Company as well as Smith Barney Shearson. He also practiced law at Cooley Godward LLP.

 

Mr. Hurwitz earned his JD from the School of Law at U.C. Berkeley, his MBA from Berkeley’s Haas School of Business, and his BA in molecular biology from Cornell University.